Avrupa Birliği - İtalyanca - EMA (European Medicines Agency)

pfizer europe ma eeig - crizotinib - carcinoma, polmone non a piccole cellule - agenti antineoplastici - xalkori as monotherapy is indicated for:the first‑line treatment of adults with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with previously treated anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with ros1‑positive advanced non‑small cell lung cancer (nsclc)the treatment of paediatric patients (age ≥6 to.

Avrupa Birliği - İtalyanca - EMA (European Medicines Agency)

diurnal europe b.v. - idrocortisone - insufficienza surrenale - corticosteroidi per uso sistemico - la terapia sostitutiva dell'insufficienza surrenalica nei neonati, bambini e adolescenti (dalla nascita a < 18 anni).

İtalya - İtalyanca - Ministero della Salute

alk abell� a.s. - dispositivi taglienti monouso - altri

İsviçre - İtalyanca - Swissmedic (Swiss Agency for Therapeutic Products)

aspen pharma schweiz gmbh - melphalanum - compresse rivestite con film - melphalanum 2 mg, cellulosum microcristallinum, crospovidonum, silica colloidalis anhydrica, magnesii stearas, Überzug: hypromellosum, macrogolum 400, e 171, pro compresso obducto. - farmaco - synthetika

İsviçre - İtalyanca - Swissmedic (Swiss Agency for Therapeutic Products)

dr. falk pharma ag - mesalazinum - suppositorien - mesalazinum 250 mg, adeps solidus, pro suppositorio. - la colite ulcerosa - synthetika

İsviçre - İtalyanca - Swissmedic (Swiss Agency for Therapeutic Products)

dr. falk pharma ag - mesalazinum - suppositorien - mesalazinum 500 mg, adeps solidus, alcohol cetylicus 18 mg, natrii docusas, pro suppositorio. - la colite ulcerosa - synthetika

İsviçre - İtalyanca - Swissmedic (Swiss Agency for Therapeutic Products)

dr. falk pharma ag - mesalazinum - suppositorien - mesalazinum 1000 mg, adeps solidus, pro suppositorio. - la colite ulcerosa - synthetika

İsviçre - İtalyanca - Swissmedic (Swiss Agency for Therapeutic Products)

dr. falk pharma ag - mesalazinum - klysmen - mesalazinum 4 g, xanthani gomma, carbomerum 934, dinatrii edetas, kalii acetas, e 224, e 211 60 mg, acqua purificata q.s. la sospensione per 60 g, per la nave. - la colite ulcerosa - synthetika

İsviçre - İtalyanca - Swissmedic (Swiss Agency for Therapeutic Products)

dr. falk pharma ag - mesalazinum - klysmen - mesalazinum 2 g, xanthani gomma, carbomerum 934, dinatrii edetas, kalii acetas, e 224, e 211 30 mg, acqua purificata q.s. la sospensione per 30 g, per la nave. - la colite ulcerosa - synthetika

İsviçre - İtalyanca - Swissmedic (Swiss Agency for Therapeutic Products)

dr. falk pharma ag - mesalazinum - granulat - mesalazinum 500 mg, cellulosum microcristallinum, hypromellosum, silica colloidalis anhydrica, acidi ethacrylici et methylis methacrylatis polymerisatum, magnesii stearas, simeticonum, methylcellulosum, acidum sorbicum, acidi methacrylici et methylis methacrylatis polymerisatum 1:1, triethylis citras, talcum, carmellosum natricum, acidum citricum, povidonum k 24-27, e 171, aromatica (vanille-creme), aspartamum 1 mg, ad granulatum, pro charta 930 mg corresp. natrium 1.62 mg. - la colite ulcerosa - synthetika